Our Reporters Discuss Healthcare Costs — And What Changes the Midterms May Portend
KFF Health News journalists made the rounds on national and local media in recent weeks to discuss topical stories. Here’s a collection of their appearances.
Drugs
1-20 of 1,325 results
-
-
Medicare Drug Plans Are Hiking Premiums While Trump Claims Victory on Medicine Prices
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase by switching to lower-cost plans.
-
‘Go to Canada’: Trump Touted Americans’ Access to Cheaper Drugs. A New Rule Threatens It.
The Trump administration pushed back a rule — until after the midterm elections — that would complicate Americans’ access to less expensive medication imports from Canada and other countries.
By Arthur Allen -
As Politicians Argue About China, US Patients Find Cutting-Edge Treatment There
The rapid emergence of the Chinese biotech industry has panicked U.S. politicians, but investors and patients caution that a clampdown on pharmaceutical collaboration could hurt everyone.
By Arthur Allen -
More Medications, More Risks. If You’re Worried, Start a Deprescribing Discussion.
As people take a greater number of medications across years or decades, experts say the risk for adverse drug interactions increases. One way to advocate for yourself? Keep a list of your meds handy.
-
Readers Are Pleading To Make American Healthcare Greater
KFF Health News gives readers a chance to comment on a recent batch of stories.
-
Four Red Flags and One Truth Amid the Peptide Hype
Experimental peptides are all the rage on longevity and “optimization” podcasts, but a lot of the chatter is misleading.
By Amy Maxmen -
People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA’s Push for Medical Freedom.
People who have taken experimental peptides, such as BPC-157, complain of migraines, eye pain, fatigue, and more. Learning whether these popular but unproven drugs are to blame may become harder if Robert F. Kennedy Jr. fulfills a promise to make them more accessible.
By Amy Maxmen -
Doctors Should Keep an Eye on Your Mix of Medication. If They Don’t, You Should.
There’s a term for reducing unnecessary or harmful drugs: “deprescribing.” Especially as patients age, experts say, it’s important to regularly review the medications they’re taking.
By Paula Span -
Journalists Evaluate Rural Voter Sentiment, MAHA Movement, and Gene-Editing Finding
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
-
They Resisted Giving Their Mom Sedating Drugs. Her Memory Care Facility Said She Had To Leave.
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
By Jordan Rau -
Patient Dies by Suicide After ‘Insurance Issue’ Delayed Medicine for Lung Disease Flare-Ups
Hours after experiencing a flare-up related to chronic obstructive pulmonary disease, Kenney Blewett of Kyle, Texas, died by suicide in June. A medication his doctor prescribed days earlier to ease his breathing problems hadn’t been filled due to an “insurance issue,” his pharmacy explained via email.
-
Republicans and Democrats Find a Unifying Target: Pharmacy Benefit Managers
Some states have considered barring companies that own a PBM from also owning brick-and-mortar pharmacies, as CVS does. Two states have followed through. A similar proposal at the federal level has gained prominent sponsors, aligning conservative, business-friendly Republicans with Democrats traditionally more open to government regulation.
-
Insurance Coverage Lags as Cancer Science, Treatment Move Forward
“Brain cancer” or “H4 G34-mutant”? As knowledge about genetics advances, some doctors say cancers should be defined by their mutations, not the tissues where they manifest.
By Arthur Allen -
The Drugs and Devices Have Been on the Market for Years. But FDA-Ordered Studies Still Aren’t Done.
To get drugs and devices out faster, the FDA lets companies conduct studies of safety or efficacy after the products are approved. In many cases, such “postmarket” studies are behind schedule or overdue, records show.
-
3 Common Drugs Older Adults Might Be Overusing
Not all older people need benzodiazepines, antibiotics, or daily aspirin — and taking them can carry increased risks.
By Paula Span -
Watch: Mark Cuban Says You Can’t Fix Healthcare Until Every Price Is Known
With his online pharmacy, Mark Cuban changed how generic drugs are sold — and he has thoughts about how to fix the healthcare system. The billionaire businessman talks to KFF Health News’ Julie Rovner to answer the question: “How Would You Fix It?”
By Julie Rovner and Hannah Norman -
How Much of a Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved Dosages
Patients and researchers point to evidence that many cancer drug dosages are excessive, and that reducing the amount and frequency could save billions of dollars and prevent some of the worst side effects.
By Arthur Allen -
Newsom Promotes Affordable Insulin, but California’s Generic Label Off to a Slow Start
California is the first to launch state-branded insulin as Gov. Gavin Newsom tries to disrupt the pharmaceutical industry. But the new CalRx drug label has been slow to reach pharmacies and patients.
By Angela Hart -
Watch: Why Abortions Are on the Rise Since ‘Roe’ Was Overturned
The way people undergo abortions has changed. This video details five things to know.
By Kate Wells and Hannah Norman